

Joseph L Kuti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4532858/joseph-l-kuti-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140
papers

3,525
citations

31
h-index

55
g-index

148
ext. papers

4,172
ext. citations

5.3
avg, IF

5.45
L-index

#	Paper	IF	Citations
140	In vitro Time Kill of Trimethoprim/Sulfamethoxazole against versus using Cation Adjusted Muller Hinton Broth and ISO-Sensitest Broth.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , aac0216721	5.9	1
139	Minocycline pharmacodynamics against <i>Stenotrophomonas maltophilia</i> in the neutropenic murine infection model: implications for susceptibility breakpoints.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	1
138	Pharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Man.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 833189	5.6	3
137	Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106603	14.3	0
136	1103. Minocycline (MIN) Pharmacodynamics (PD) against <i>Stenotrophomonas maltophilia</i> (STM) in a Neutropenic Murine Thigh Infection Model. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S643-S643	1	
135	Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106299	14.3	10
134	Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against <i>Pseudomonas aeruginosa</i> from patients with cystic fibrosis. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021 , 20, 9	6.2	4
133	A guide to therapeutic drug monitoring of β -lactam antibiotics. <i>Pharmacotherapy</i> , 2021 , 41, 220-233	5.8	15
132	Optimised cefiderocol exposures in a successfully treated critically ill patient with polymicrobial <i>Stenotrophomonas maltophilia</i> bacteraemia and pneumonia receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2021 , 58, 106395	14.3	3
131	1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S646-S646	1	
130	58. Impact of Order-set Modifications and Provider Education on Broad-Spectrum Antibiotic Use in Patients Admitted with Community Acquired Pneumonia. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S147-S148	1	
129	1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S635-S635	1	0
128	65. In Vivo Efficacy of Human Simulated Minocycline (MIN) against <i>Stenotrophomonas maltophilia</i> (STM). <i>Open Forum Infectious Diseases</i> , 2021 , 8, S44-S44	1	
127	A Retrospective Case Series of Concomitant Carbapenem and Valproic Acid Use: Are Best Practice Advisories Working?. <i>Journal of Pharmacy Practice</i> , 2021 , 8971900211063301	1.3	
126	Development of Daptomycin Susceptibility Breakpoints for <i>Enterococcus faecium</i> and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1240-1246	11.6	15
125	Unresolved issues in the identification and treatment of carbapenem-resistant Gram-negative organisms. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 482-494	5.4	1
124	Assessment of Meropenem and Vaborbactam Room Temperature and Refrigerated Stability in Polyvinyl Chloride Bags and Elastomeric Devices. <i>Clinical Therapeutics</i> , 2020 , 42, 606-613	3.5	1

123	Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1546-1553	5.1	24
122	1317. Pharmacokinetics (PK) of Ampicillin-Sulbactam (SAM) during Orthotopic Liver Transplantation (OLT). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S670-S670	1	0
121	1308. Ex vivo Impact of Autologous Blood Transfusion (ABT) on Concentrations of Antibiotics used for Surgical Prophylaxis. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S667-S667	1	
120	13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S7-S8	1	
119	1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S797-S797	1	
118	112. Impact of Respiratory Viral PCR Panels (RVP) and Serum Procalcitonin (PCT) on Antibiotic Days of Therapy (DOT) in Patients Admitted with Lower Respiratory Tract Infections (LRTI). <i>Open Forum Infectious Diseases</i> , 2020 , 7, S70-S70	1	
117	1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model. <i>Open Forum Infectious Diseases</i> , 2020 , 7, S667-S667	1	
116	Monte Carlo Simulation Methodologies for β -Lactam/ β -Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. <i>Journal of Clinical Pharmacology</i> , 2020 , 60, 172-180	2.9	5
115	Impact of Intraoperative Cell Salvage on Concentrations of Antibiotics Used for Surgical Prophylaxis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	1
114	Imipenem/Cilastatin/Relebactam Alone and in Combination against in the Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	2
113	Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections. <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 705-720	5.5	8
112	Critique of prevention of pneumococcal disease in high risk adults: A pharmacist-based assessment of adult immunization protocols in clinical practice. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2019 , 2, 444-445	1.4	
111	Effect of Clinically Meaningful Antibiotic Concentrations on Recovery of Escherichia coli and Klebsiella pneumoniae Isolates from Anaerobic Blood Culture Bottles with and without Antibiotic Binding Resins. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	5
110	Carbapenem-Nonsusceptible Isolates from Intensive Care Units in the United States: a Potential Role for New β -Lactam Combination Agents. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	21
109	Pharmacodynamics of a Novel Ceftibuten-Clavulanate Combination Antibiotic against Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	7
108	Where should antibiotic gradient diffusion strips be crossed to assess synergy? A comparison of the standard method with a novel method using steady-state antimicrobial concentrations. <i>International Journal of Antimicrobial Agents</i> , 2019 , 53, 698-702	14.3	2
107	Reply to Cheng and Chuang. <i>Clinical Infectious Diseases</i> , 2019 , 69, 903-904	11.6	0
106	Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5

105	Recovery of Gram-Negative Bacteria from Aerobic Blood Culture Bottles Containing Antibiotic Binding Resins after Exposure to β -Lactam and Fluoroquinolone Concentrations. <i>Journal of Clinical Microbiology</i> , 2019 , 57,	9.7	4
104	A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. <i>Clinical Therapeutics</i> , 2019 , 41, 1453-1462	3.5	7
103	Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007). <i>Infectious Diseases and Therapy</i> , 2019 , 8, 383-396	6.2	8
102	Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	13
101	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 346-350	14.3	5
100	Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2019 , 41, 2162-2170	3.5	1
99	Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 64,	5.9	4
98	888. <i>Critical Care Medicine</i> , 2019 , 47, 423	1.4	1
97	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1650-1657	11.6	22
96	Pharmacokinetic and Pharmacodynamic Analysis of Ceftazidime/Avibactam in Critically Ill Patients. <i>Surgical Infections</i> , 2019 , 20, 55-61	2	22
95	Is One Sample Enough? β -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
94	Efficacy of Human-Simulated Exposures of Ceftolozane-Tazobactam Alone and in Combination with Amikacin or Colistin against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> in an Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	17
93	Meropenem time above the MIC exposure is predictive of response in cystic fibrosis children with acute pulmonary exacerbations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 294-297	2.9	10
92	Novel pharmacotherapy for the treatment of hospital-acquired and ventilator-associated pneumonia caused by resistant gram-negative bacteria. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 397-408	4	15
91	Physical Compatibility of Meropenem and Vaborbactam With Select Intravenous Drugs During Simulated Y-site Administration. <i>Clinical Therapeutics</i> , 2018 , 40, 261-269	3.5	10
90	Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> and <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	9
89	Defining the potency of amikacin against , and derived from Chinese hospitals using CLSI and inhalation-based breakpoints. <i>Infection and Drug Resistance</i> , 2018 , 11, 783-790	4.2	11
88	Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11

87	Patient preferences for treatment of acute bacterial skin and skin structure infections in the emergency department. <i>BMC Health Services Research</i> , 2018 , 18, 932	2.9	9
86	Variability in Emergency Medicine Provider Decisions on Hospital Admission and Antibiotic Treatment in a Survey Study for Acute Bacterial Skin and Skin Structure Infections: Opportunities for Antimicrobial Stewardship Education. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy206	1	2
85	1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI). <i>Open Forum Infectious Diseases</i> , 2018 , 5, S47-S47	1	78
84	1398. Lactam Probability of Target Attainment (PTA) and Penetration into Epithelial Lining Fluid (ELF) Based on Multiple Bronchoalveolar Lavage (BAL) Sampling Time Points in a Swine Pneumonia Model. <i>Open Forum Infectious Diseases</i> , 2018 , 5, S430-S430	1	78
83	Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, e36-e44	2.2	7
82	Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 1048-1056	2.2	6
81	Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 712-719	2.9	19
80	Physical compatibility of isavuconazonium sulfate with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, e55-e63	2.2	1
79	Effects of Clinically Meaningful Concentrations of Antipseudomonal Lactams on Time to Detection and Organism Growth in Blood Culture Bottles. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 3502-3512	2.7	6
78	Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	11
77	Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. <i>Journal of Pharmacy Practice</i> , 2017 , 30, 593-599	1.3	1
76	Defining the impact of severity of illness on time above the MIC threshold for cefepime in Gram-negative bacteraemia: a Goldilocks window. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 487-490	14.3	13
75	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 617-633	6.2	33
74	Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 189-95	5.1	15
73	Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 6578-6584	5.9	31
72	Treatment of multidrug-resistant <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 342-3	14.3	31
71	Continuous and Prolonged Intravenous Lactam Dosing: Implications for the Clinical Laboratory. <i>Clinical Microbiology Reviews</i> , 2016 , 29, 759-72	34	32
70	The Essential Role of Pharmacists in Antimicrobial Stewardship. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 753-4	2	32

69	In Vitro Pharmacodynamics of Human Simulated Exposures of Telavancin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> with and without Prior Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 222-8	5.9	1
68	Tissue penetration and exposure of cefepime in patients with diabetic foot infections. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 247-8	14.3	3
67	An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 78-83	2.2	19
66	Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 459-76	3.8	21
65	Stability of Ertapenem 100 mg/mL at Room Temperature. <i>Canadian Journal of Hospital Pharmacy</i> , 2016 , 69, 256-9	0.5	1
64	Assessment of <i>Clostridium difficile</i> Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 215-8	2	14
63	Antibiotic Utilization and Opportunities for Stewardship Among Hospitalized Patients With Influenza Respiratory Tract Infection. <i>Infection Control and Hospital Epidemiology</i> , 2016 , 37, 583-9	2	19
62	In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant <i>Staphylococcus aureus</i> : Considering the Variability in Observed Tissue Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 955-61	5.9	5
61	COMO OPTIMIZAR LA FARMACODINAMIA ANTIMICROBIANA: UNA GUÍA PARA UN PROGRAMA DE OPTIMIZACIÓN DEL USO DE ANTIMICROBIANOS. <i>Revista Médica Clínica Las Condes</i> , 2016 , 27, 625-635	0.2	
60	Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 512-8	14.3	6
59	Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against <i>Pseudomonas aeruginosa</i> isolated from children with cystic fibrosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015 , 83, 53-5	2.9	31
58	Vancomycin serum concentrations do not adequately predict tissue exposure in diabetic patients with mild to moderate limb infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2064-7	5.1	14
57	Defining Clinical Exposures of Cefepime for Gram-Negative Bloodstream Infections That Are Associated with Improved Survival. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1401-10	5.9	35
56	Mortality, Hospital Costs, Payments, and Readmissions Associated With Infection Among Medicare Beneficiaries. <i>Infectious Diseases in Clinical Practice</i> , 2015 , 23, 318-323	0.2	17
55	Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. <i>Lancet Infectious Diseases</i> , 2014 , 14, 498-509	25.5	534
54	Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. <i>Clinical Infectious Diseases</i> , 2014 , 59, 905-7	11.6	20
53	Prolonging β -lactam infusion: a review of the rationale and evidence, and guidance for implementation. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 105-13	14.3	49
52	In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 874-8	5.9	52

51	In vitro activity of human-simulated epithelial lining fluid exposures of ceftaroline, ceftriaxone, and vancomycin against methicillin-susceptible and -resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 7520-6	5.9	15
50	Population Pharmacokinetics of Cefazolin in Serum and Tissue for Patients with Complicated Skin and Soft Tissue Infections (cSSTI). <i>Infectious Diseases and Therapy</i> , 2014 , 3, 269-79	6.2	10
49	In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 672-7	5.9	18
48	Clinical pharmacodynamics of antipseudomonal cephalosporins in patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1359-64	5.9	55
47	Stability of ertapenem 100 mg/mL in polypropylene syringes stored at 25, 4, and -20 °C. <i>American Journal of Health-System Pharmacy</i> , 2014 , 71, 1480-4	2.2	5
46	Population pharmacokinetics of piperacillin/tazobactam in critically ill young children. <i>Pediatric Infectious Disease Journal</i> , 2014 , 33, 168-73	3.4	47
45	Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers. <i>Pharmacotherapy</i> , 2013 , 33, 266-74	5.8	28
44	In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 202-7	5.9	54
43	Optimization of meropenem dosage in the critically ill population based on renal function. <i>Intensive Care Medicine</i> , 2011 , 37, 632-8	14.5	69
42	Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration. <i>American Journal of Health-System Pharmacy</i> , 2011 , 68, 2265-70	2.2	7
41	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant <i>Staphylococcus aureus</i> with a range of vancomycin MICs in a murine pneumonia model. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5115-9	5.9	49
40	Clinical pharmacodynamics of cefepime in patients infected with <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 1111-6	5.9	89
39	Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. <i>Journal of Critical Care</i> , 2010 , 25, 69-77	4	65
38	Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis [A review of 3 cases. <i>Respiratory Medicine CME</i> , 2010 , 3, 146-149		12
37	Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. <i>Pharmacotherapy</i> , 2010 , 30, 453-62	5.8	24
36	Pharmacotherapy of Complicated Urinary Tract and Intra-abdominal Infections with Doripenem. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S2062		
35	Tackling empirical antibiotic therapy for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2009 , 30, 102-15	3.9	16
34	Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 1476-81	5.9	89

33	Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric population. <i>Pediatric Blood and Cancer</i> , 2009 , 53, 379-85	3	60
32	Elevated vancomycin minimum inhibitory concentrations among methicillin-resistant <i>Staphylococcus aureus</i> isolated from patients with ventilator-associated pneumonia at a Connecticut hospital. <i>Connecticut Medicine</i> , 2009 , 73, 337-40		2
31	Influence of automated screening and confirmation of extended-spectrum beta-lactamase-producing members of the Enterobacteriaceae on prescribing of antibiotics. <i>Journal of Medical Microbiology</i> , 2008 , 57, 1147-1151	3.2	
30	Pharmacodynamic performance of tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and skin structure infections. <i>Surgical Infections</i> , 2008 , 9, 57-66	2	6
29	Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. <i>International Journal of Antimicrobial Agents</i> , 2007 , 30, 452-7	14.3	25
28	Optimal dosing of piperacillin-tazobactam for the treatment of <i>Pseudomonas aeruginosa</i> infections: prolonged or continuous infusion?. <i>Pharmacotherapy</i> , 2007 , 27, 1490-7	5.8	63
27	Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1725-30	5.9	208
26	Treatment of <i>Serratia marcescens</i> meningitis with prolonged infusion of meropenem. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 1077-81	2.9	20
25	Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. <i>Clinical Therapeutics</i> , 2007 , 29, 889-899	3.5	12
24	Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 58, 337-44	2.9	47
23	Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 69-75	2.9	36
22	Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. <i>Drugs</i> , 2006 , 66, 1-14	12.1	68
21	Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. <i>International Journal of Antimicrobial Agents</i> , 2006 , 28, 62-8	14.3	23
20	Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against <i>Pseudomonas aeruginosa</i> infections in children: a report from the OPTAMA program. <i>Clinical Therapeutics</i> , 2005 , 27, 1820-30	3.5	24
19	Making the most of surveillance studies: summary of the OPTAMA Program. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005 , 53, 281-7	2.9	30
18	Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. <i>Pharmacotherapy</i> , 2005 , 25, 935-41	5.8	21
17	Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2005 , 56, 388-95	5.1	81
16	Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. <i>Chemotherapy</i> , 2005 , 51, 211-6	3.2	11

15	IV to Oral Conversion Programs for Anti-Infectives in the United States: Prevalence and Characteristics. <i>Hospital Pharmacy</i> , 2004 , 39, 1069-1075	1.1	1
14	Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. <i>Pharmacotherapy</i> , 2004 , 24, 8-15	5.8	28
13	Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: application of pharmacodynamic concepts to meropenem therapy. <i>Pharmacotherapy</i> , 2004 , 24, 1641-5	5.8	30
12	Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 2464-70	5.9	89
11	Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. <i>Pharmacoeconomics</i> , 2004 , 22, 301-10	4.4	16
10	Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. <i>Clinical Therapeutics</i> , 2004 , 26, 1187-98	3.5	85
9	Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis. <i>Clinical Therapeutics</i> , 2004 , 26, 493-501	3.5	60
8	Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. <i>American Journal of Health-System Pharmacy</i> , 2003 , 60, 565-8	2.2	29
7	Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 1116-23	2.9	143
6	Antibiotic treatment of catheter-related bacteremia in the hemodialysis patient. <i>Connecticut Medicine</i> , 2003 , 67, 85-8		
5	Pharmacoeconomics of a pharmacist-managed program for automatically converting levofloxacin route from i.v. to oral. <i>American Journal of Health-System Pharmacy</i> , 2002 , 59, 2209-15	2.2	45
4	Cefditoren Pivoxil. <i>Drugs</i> , 2002 , 62, 337-338	12.1	1
3	Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. <i>Pharmacoeconomics</i> , 2002 , 20, 513-28	4.4	19
2	Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2002 , 44, 51-7	2.9	34
1	Impact of Order-Set Modifications and Provider Education Following Guideline Updates on Broad-Spectrum Antibiotic Use in Patients Admitted With Community Acquired Pneumonia. <i>Hospital Pharmacy</i> , 001857872110557	1.1	